*Kira Out-Licenses KP-301, Long-Acting anti-C5a Monoclonal Antibody, and KP-402, Small Molecule C5a Receptor Antagonist, to Mirador Therapeutics, for $12 M

Dow Jones · 1d ago

Please log in to view news